Latest & greatest articles for latanoprost

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on latanoprost or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on latanoprost and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for latanoprost

1. Latanoprost

Latanoprost Top results for latanoprost - Trip Database or use your Google+ account Find evidence fast My query is: English Français Deutsch Čeština Español Magyar Svenska ALL of these words: Title only Anywhere in the document ANY of these words: Title only Anywhere in the document This EXACT phrase: Title only Anywhere in the document EXCLUDING words: Title only Anywhere in the document Timeframe: to: Combine searches by placing the search numbers in the top search box and pressing the search (...) button. An example search might look like (#1 or #2) and (#3 or #4) Loading history... Population: Intervention: Comparison: Outcome: Population: Intervention: Latest & greatest articles for latanoprost The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory

Trip Latest and Greatest2018

2. latanoprost (Monoprost )

latanoprost (Monoprost ) latanoprost | CADTH.ca Find the information you need latanoprost Generic Name: latanoprost Brand Name: Monoprost Manufacturer: Laboratoires Théa Indications: glaucoma and ocular hypertension Submission Type: New Project Status: Pending Call For Patient Input: September 26, 2017 Patient Input Closed: November 15, 2017 Anticipated Date: October 25, 2017 Biosimilar: No Fee Schedule 1 : Pending Follow us: © 2017 Canadian Agency for Drugs and Technologies in Health Get our

Canadian Agency for Drugs and Technologies in Health - Common Drug Review2018

3. Netarsudil plus latanoprost (Roclatan) for glaucoma or ocular hypertension

Netarsudil plus latanoprost (Roclatan) for glaucoma or ocular hypertension Netarsudil plus latanoprost (Roclatan) for glaucoma or ocular hypertension ‐ NIHR Innovation Observatory ☰ Menu Search Filter by Specialty Filter by Year Netarsudil plus latanoprost (Roclatan) for glaucoma or ocular hypertension September 2017 Technology Description: Glaucoma describes a group of disorders characterised by sight loss. Glaucoma is generally associated with high pressure in the liquids inside the eye (...) . If the eye drops do not work and glaucoma is diagnosed, laser therapy or eye surgery can also be used to stop sight loss. Roclatan is a fixed dose combination of two drugs, netarsudil and latanoprost, which is widely used to treat eye pressure. Individually, both drugs act in different and unique ways to lower the pressure in the eye. When used in combination, both drugs have a potential to produce a stronger and more sustained effect. If licenced, Roclatan has the potential to be more effective

NIHR Innovation Observatory2017

4. Latanoprost (Xalatan): increased reporting of eye irritation since reformulation

Latanoprost (Xalatan): increased reporting of eye irritation since reformulation Latanoprost (Xalatan): increased reporting of eye irritation since reformulation - GOV.UK GOV.UK uses cookies to make the site simpler. Search Latanoprost (Xalatan): increased reporting of eye irritation since reformulation From: Published: 20 July 2015 Therapeutic area: Advise patients to tell their health professional if they experience severe eye irritation. Contents When prescribing or dispensing the Xalatan (...) brand of latanoprost: advise patients to tell their health professional if they experience severe eye irritation review treatment if patients mention severe eye irritation please continue to report suspected side effects to latanoprost or any other medicines on a Xalatan is an eye-drop formulation of latanoprost. It is licensed for the reduction of intraocular pressure in adults and children with ocular hypertension and open angle glaucoma. In 2013, the Xalatan pH was reduced from 6.7 to 6.0

MHRA Drug Safety Update2015

5. Latanoprost for open-angle glaucoma (UKGTS): a randomised, multicentre, placebo-controlled trial.

Latanoprost for open-angle glaucoma (UKGTS): a randomised, multicentre, placebo-controlled trial. BACKGROUND: Treatments for open-angle glaucoma aim to prevent vision loss through lowering of intraocular pressure, but to our knowledge no placebo-controlled trials have assessed visual function preservation, and the observation periods of previous (unmasked) trials have typically been at least 5 years. We assessed vision preservation in patients given latanoprost compared with those given placebo (...) . METHODS: In this randomised, triple-masked, placebo-controlled trial, we enrolled patients with newly diagnosed open-angle glaucoma at ten UK centres (tertiary referral centres, teaching hospitals, and district general hospitals). Eligible patients were randomly allocated (1:1) with a website-generated randomisation schedule, stratified by centre and with a permuted block design, to receive either latanoprost 0·005% (intervention group) or placebo (control group) eye drops. Drops were administered

Lancet2015

6. Latanoprost for open-angle glaucoma (UKGTS): a randomised, multicentre, placebo-controlled trial.

Latanoprost for open-angle glaucoma (UKGTS): a randomised, multicentre, placebo-controlled trial. 25533656 2015 04 20 2015 04 29 2015 09 04 1474-547X 385 9975 2015 Apr 04 Lancet (London, England) Lancet Latanoprost for open-angle glaucoma (UKGTS): a randomised, multicentre, placebo-controlled trial. 1295-304 10.1016/S0140-6736(14)62111-5 S0140-6736(14)62111-5 Treatments for open-angle glaucoma aim to prevent vision loss through lowering of intraocular pressure, but to our knowledge no placebo (...) -controlled trials have assessed visual function preservation, and the observation periods of previous (unmasked) trials have typically been at least 5 years. We assessed vision preservation in patients given latanoprost compared with those given placebo. In this randomised, triple-masked, placebo-controlled trial, we enrolled patients with newly diagnosed open-angle glaucoma at ten UK centres (tertiary referral centres, teaching hospitals, and district general hospitals). Eligible patients were randomly

Lancet2014

7. Relative efficacy and safety of preservative-free Latanoprost (T2345) for the treatment of open-angle glaucoma and ocular hypertension: an adjusted indirect comparison meta-analysis of randomized clinical trials

Relative efficacy and safety of preservative-free Latanoprost (T2345) for the treatment of open-angle glaucoma and ocular hypertension: an adjusted indirect comparison meta-analysis of randomized clinical trials Relative efficacy and safety of preservative-free Latanoprost (T2345) for the treatment of open-angle glaucoma and ocular hypertension: an adjusted indirect comparison meta-analysis of randomized clinical trials Relative efficacy and safety of preservative-free Latanoprost (T2345 (...) ) for the treatment of open-angle glaucoma and ocular hypertension: an adjusted indirect comparison meta-analysis of randomized clinical trials Cucherat M, Stalmans I, Rouland JF CRD summary The authors concluded that preservative-free latanoprost (T2345) was better tolerated and no less effective than all other prostaglandin analogues assessed. All comparisons except one were indirect so there was insufficient data from direct comparisons to assess the validity of the indirect comparisons and the authors

DARE.2014

8. Latanoprost

Latanoprost USE OF LATANOPROST IN PREGNANCY 0344 892 0909 USE OF LATANOPROST IN PREGNANCY (Date of issue: February 2016 , Version: 2 ) This is a UKTIS monograph for use by health care professionals. For case-specific advice please contact UKTIS on 0344 892 0909. To report an exposure please download and complete a . Please encourage all women to complete an . Summary Latanoprost is a prostaglandin analogue used topically in the treatment of ocular hypertension and open-angle glaucoma. Systemic (...) use of prostaglandins can increase uterine tone, have known abortifacient effects, and may also cause reduced placental perfusion to the fetus, raising concerns regarding their use during pregnancy. However, latanoprost is currently only licensed for ocular administration, therefore a high systemic concentration following use would not be expected at the recommended therapeutic dose of 1.5 micrograms/day. There are no large epidemiological studies on the use of latanoprost during pregnancy

UK Teratology Information Service2014

9. Latanoprost (Monopost) - for the reduction of elevated intraocular pressure in patients with open angle glaucoma and ocular hypertension

Latanoprost (Monopost) - for the reduction of elevated intraocular pressure in patients with open angle glaucoma and ocular hypertension Published 08 July 2013 Product Update: latanoprost 50microgram/mL preservative-free single-dose eye-drops (Monopost®) (No: 879/13) Spectrum Thea Pharmaceuticals Ltd 07 June 2013 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and advises NHS Boards and Area Drug and Therapeutic Committees (ADTCs) on its use in NHS (...) Scotland. The advice is summarised as follows: ADVICE: following an abbreviated submission latanoprost preservative-free eye-drops (Monopost®) are accepted for restricted use within NHS Scotland. Indication under review: for the reduction of elevated intraocular pressure in patients with open angle glaucoma and ocular hypertension. SMC restriction: to use in patients who have proven sensitivity to the preservative benzalkonium chloride. SMC has previously accepted preserved latanoprost eye-drops

Scottish Medicines Consortium2013

10. Latanoprost versus timolol as first choice therapy in patients with ocular hypertension

Latanoprost versus timolol as first choice therapy in patients with ocular hypertension Latanoprost versus timolol as first choice therapy in patients with ocular hypertension Latanoprost versus timolol as first choice therapy in patients with ocular hypertension Peeters A, Schouten JS, Severens JL, Hendrikse F, Prins MH, Webers CA Record Status This is an economic evaluation that meets the criteria for inclusion on NHS EED. CRD summary The study examined the cost-effectiveness of first-line (...) treatment with either latanoprost or timolol for the management of ocular hypertension. The authors concluded that treatment starting with latanoprost was not cost-effective compared with treatment starting with timolol because of small differences in health benefits and the high price of latanoprost. The analysis was based on a valid modelling framework. The authors’ conclusions appear robust. Type of economic evaluation Cost-effectiveness analysis Study objective The study examined the cost

NHS Economic Evaluation Database.2012

11. Treatment persistence and cost-effectiveness of latanoprost/latanoprost-timolol, bimatoprost/bimatoprost-timolol, and travoprost/travoprost-timolol in glaucoma: an analysis based on the United Kingdom general practitioner research database

Treatment persistence and cost-effectiveness of latanoprost/latanoprost-timolol, bimatoprost/bimatoprost-timolol, and travoprost/travoprost-timolol in glaucoma: an analysis based on the United Kingdom general practitioner research database Treatment persistence and cost-effectiveness of latanoprost/latanoprost-timolol, bimatoprost/bimatoprost-timolol, and travoprost/travoprost-timolol in glaucoma: an analysis based on the United Kingdom general practitioner research database Treatment (...) persistence and cost-effectiveness of latanoprost/latanoprost-timolol, bimatoprost/bimatoprost-timolol, and travoprost/travoprost-timolol in glaucoma: an analysis based on the United Kingdom general practitioner research database Lafuma A, Salmon JF, Robert J, Berdeaux G Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical

NHS Economic Evaluation Database.2011

12. Systematic review of intraocular pressure-lowering effects of adjunctive medications added to latanoprost

Systematic review of intraocular pressure-lowering effects of adjunctive medications added to latanoprost Systematic review of intraocular pressure-lowering effects of adjunctive medications added to latanoprost Systematic review of intraocular pressure-lowering effects of adjunctive medications added to latanoprost Cheng JW, Li Y, Wei RL CRD summary This review found that adjunctive medications added to latanoprost (0.005%) decreased intra-ocular pressure in patients with primary open-angle (...) glaucoma or ocular hypertension, especially with timolol (0.5% once daily). The limitations of the data and review methods, particularly the flaws in the analysis, mean that the findings of the review are unlikely to be reliable and should be interpreted with caution. Authors' objectives To evaluate the intra-ocular pressure-lowering effects of adjunctive medications added to latanoprost in patients with primary open-angle glaucoma or ocular hypertension. Searching PubMed, EMBASE and the Cochrane

DARE.2009

13. Cost effectiveness of travoprost versus a fixed combination of latanoprost/timolol in patients with ocular hypertension or glaucoma: analysis based on the UK General Practitioner Research Database

Cost effectiveness of travoprost versus a fixed combination of latanoprost/timolol in patients with ocular hypertension or glaucoma: analysis based on the UK General Practitioner Research Database Cost effectiveness of travoprost versus a fixed combination of latanoprost/timolol in patients with ocular hypertension or glaucoma: analysis based on the UK General Practitioner Research Database Cost effectiveness of travoprost versus a fixed combination of latanoprost/timolol in patients (...) in comparison with a fixed combination of latanoprost and timolol (LT) as first-line therapy for ocular hypertension or glaucoma. The authors concluded that first-line treatment with travoprost was maintained longer than LT and halved the cost of care, but differences in the disease severity between the two groups might have affected the validity of these findings. The study had some methodological limitations and caution is required when interpreting the authors’ conclusions. Type of economic evaluation

NHS Economic Evaluation Database.2009

14. Cost-effectiveness of latanoprost and timolol maleate for the treatment of glaucoma in Scandinavia and the United Kingdom, using a decision-analytic health economic model

Cost-effectiveness of latanoprost and timolol maleate for the treatment of glaucoma in Scandinavia and the United Kingdom, using a decision-analytic health economic model Cost-effectiveness of latanoprost and timolol maleate for the treatment of glaucoma in Scandinavia and the United Kingdom, using a decision-analytic health economic model Cost-effectiveness of latanoprost and timolol maleate for the treatment of glaucoma in Scandinavia and the United Kingdom, using a decision-analytic health (...) economic model Stewart W C, Stewart J A, Mychaskiw M A Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary The objective was to examine the long-term cost-effectiveness of latanoprost versus timolol as monotherapy for the treatment of open

NHS Economic Evaluation Database.2009

15. Efficacy and tolerability of latanoprost compared to dorzolamide combined with timolol in the treatment of patients with elevated intraocular pressure: a meta-analysis of randomized, controlled trials

Efficacy and tolerability of latanoprost compared to dorzolamide combined with timolol in the treatment of patients with elevated intraocular pressure: a meta-analysis of randomized, controlled trials Efficacy and tolerability of latanoprost compared to dorzolamide combined with timolol in the treatment of patients with elevated intraocular pressure: a meta-analysis of randomized, controlled trials Efficacy and tolerability of latanoprost compared to dorzolamide combined with timolol (...) in the treatment of patients with elevated intraocular pressure: a meta-analysis of randomized, controlled trials Cheng JW, Xi GL, Wei RL, Cai JP, Li Y CRD summary The review found that latanoprost lowered diurnal mean intraocular pressure more than dorzolamide with timolol in patients insufficiently controlled by timolol alone. The treatments were equally effective in patients without baseline timolol treatment. In view of poor reporting and the large number of subgroups reported in the review, the authors

DARE.2009

16. Conjunctival hyperaemia with the use of latanoprost versus other prostaglandin analogues in patients with ocular hypertension or glaucoma: a meta-analysis of randomised clinical trials

Conjunctival hyperaemia with the use of latanoprost versus other prostaglandin analogues in patients with ocular hypertension or glaucoma: a meta-analysis of randomised clinical trials Conjunctival hyperaemia with the use of latanoprost versus other prostaglandin analogues in patients with ocular hypertension or glaucoma: a meta-analysis of randomised clinical trials Conjunctival hyperaemia with the use of latanoprost versus other prostaglandin analogues in patients with ocular hypertension or (...) glaucoma: a meta-analysis of randomised clinical trials Honrubia F, Garcia-Sanchez J, Polo V, Martinez De La Casa JM, Soto J CRD summary The authors concluded that latanoprost was associated with a lower incidence of conjunctival hyperaemia than travoprost and bimatoprost in patients with ocular hypertension or glaucoma. The review was generally well conducted and the authors’ conclusions appear appropriate. Authors' objectives To compare the rates of conjunctival hyperaemia in patients with ocular

DARE.2009

17. Meta-analysis of 13 randomized controlled trials comparing bimatoprost with latanoprost in patients with elevated intraocular pressure

Meta-analysis of 13 randomized controlled trials comparing bimatoprost with latanoprost in patients with elevated intraocular pressure Meta-analysis of 13 randomized controlled trials comparing bimatoprost with latanoprost in patients with elevated intraocular pressure Meta-analysis of 13 randomized controlled trials comparing bimatoprost with latanoprost in patients with elevated intraocular pressure Cheng J W, Wei R L CRD summary This review concluded that bimatoprost is more effective (...) in reducing morning elevated intraocular pressure (IOP) than latanoprost, and at achieving the target IOP at 3 months. Both treatments were generally well tolerated. Given several considerations with the included studies, such as clinical differences between the studies and limitations with the data synthesis, the authors’ conclusions may not be reliable. Authors' objectives To compare the efficacy and tolerability of bimatoprost with latanoprost in treating patients with elevated intraocular pressure

DARE.2008

18. Assessment of the cost effectiveness of travoprost versus latanoprost as single agents for treatment of glaucoma in France

Assessment of the cost effectiveness of travoprost versus latanoprost as single agents for treatment of glaucoma in France Assessment of the cost effectiveness of travoprost versus latanoprost as single agents for treatment of glaucoma in France Assessment of the cost effectiveness of travoprost versus latanoprost as single agents for treatment of glaucoma in France Payet S, Denis P, Berdeaux G, Launois R Record Status This is a critical abstract of an economic evaluation that meets (...) the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary The aim was to assess the costs and effects of travoprost and latanoprost as single treatments for glaucoma in France. The authors concluded that travoprost was very cost-effective, producing fewer treatment changes, at a small increase in cost, which was acceptable

NHS Economic Evaluation Database.2008

20. Meta-analysis of randomised controlled trials comparing latanoprost with brimonidine in the treatment of open-angle glaucoma, ocular hypertension or normal-tension glaucoma

Meta-analysis of randomised controlled trials comparing latanoprost with brimonidine in the treatment of open-angle glaucoma, ocular hypertension or normal-tension glaucoma Meta-analysis of randomised controlled trials comparing latanoprost with brimonidine in the treatment of open-angle glaucoma, ocular hypertension or normal-tension glaucoma Meta-analysis of randomised controlled trials comparing latanoprost with brimonidine in the treatment of open-angle glaucoma, ocular hypertension or (...) normal-tension glaucoma Fung A T, Reid S E, Jones M P, Healey P R, McCluskey P J, Craig J C CRD summary This review compared the effectiveness and adverse effects of latanoprost versus brimonidine for treating open-angle glaucoma, normal-tension glaucoma and ocular hypertension. The authors concluded that latanoprost is more effective in reducing intraocular pressure than brimonidine and that brimonidine causes more fatigue than latanoprost. The review was generally well-conducted and the conclusions

DARE.2007